Journal of Cancer Metastasis and Treatment

Scope & Guideline

Exploring breakthroughs in metastasis and therapy.

Introduction

Immerse yourself in the scholarly insights of Journal of Cancer Metastasis and Treatment with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2394-4722
PublisherOAE PUBLISHING INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationJ CANCER METAS TREAT / J. Cancer Metastasis Treat.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address245 E MAIN ST, ST122, ALHAMBRA, CA 91801

Aims and Scopes

The Journal of Cancer Metastasis and Treatment is dedicated to advancing the understanding of cancer metastasis and treatment methodologies. The journal aims to publish high-quality research that contributes to the fields of oncology, molecular biology, and therapeutic interventions in cancer care. Below are the core areas of focus:
  1. Cancer Metastasis Mechanisms:
    Exploration of the biological processes and molecular mechanisms that underlie cancer metastasis, including tumor microenvironment interactions and cellular signaling pathways.
  2. Innovative Treatment Strategies:
    Investigation of novel therapeutic approaches, including immunotherapy, targeted therapy, and emerging drug combinations that improve patient outcomes in various cancer types.
  3. Clinical Research and Trials:
    Reporting on clinical studies, trials, and retrospective analyses that provide insights into the efficacy and safety of cancer treatments across diverse patient populations.
  4. Biomarkers and Prognostic Indicators:
    Identification and validation of biomarkers that can predict treatment response, disease progression, and patient prognosis in cancer patients.
  5. Translational Research:
    Focus on bridging laboratory findings with clinical applications to enhance treatment modalities and patient care in oncology.
  6. Multidisciplinary Approaches:
    Encouragement of collaborative research that integrates various disciplines, such as surgery, radiology, and pharmacology, to address complex cancer challenges.
The journal has seen a rise in focus on several trending and emerging themes, reflecting advancements in cancer research and treatment methodologies. These themes represent the forefront of current investigations and clinical applications:
  1. Immunotherapy Innovations:
    There is an increasing volume of research dedicated to immunotherapy, including combination strategies with checkpoint inhibitors, highlighting their potential in various cancer types.
  2. Machine Learning and AI Applications:
    The integration of machine learning and artificial intelligence in analyzing clinical data and omics is gaining traction, showcasing its potential to predict treatment outcomes and personalize therapy.
  3. Microbiome and Cancer Interactions:
    Research exploring the role of the microbiome in cancer treatment responses and disease progression is emerging as a significant area of interest, emphasizing its impact on patient health.
  4. Liquid Biopsy Techniques:
    The development and application of liquid biopsy methods for early cancer detection and monitoring treatment responses are increasingly featured, reflecting a shift towards less invasive diagnostic approaches.
  5. Targeted Therapies and Personalized Medicine:
    A growing emphasis on precision medicine and the identification of molecular targets for tailored treatment strategies is evident, as researchers seek to optimize therapeutic efficacy.
  6. Cancer Stem Cell Research:
    The investigation of cancer stem cells and their role in metastasis and treatment resistance is trending, as understanding these cells is crucial for developing effective therapies.

Declining or Waning

While the Journal of Cancer Metastasis and Treatment continues to explore a wide range of themes, certain areas of focus appear to be waning in prominence. The following themes have seen a decline in recent publications:
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable shift away from discussions centered on traditional chemotherapy, as newer targeted therapies and immunotherapy options gain traction in the field.
  2. Single-Agent Therapy Studies:
    Research focusing solely on the efficacy of single-agent therapies is becoming less common, with a growing emphasis on combination therapies that enhance treatment effectiveness.
  3. Basic Cancer Biology Studies:
    While foundational research remains important, there is a decreasing emphasis on purely basic science studies without direct clinical application, as the journal leans towards translational research.
  4. Historical Treatment Protocols:
    Papers discussing outdated treatment protocols or historical perspectives on cancer management are less frequently published, reflecting a move towards contemporary practices and innovations.

Similar Journals

OncoTargets and Therapy

Transforming insights into impactful cancer solutions.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6930Frequency: 1 issue/year

OncoTargets and Therapy is a prestigious, peer-reviewed journal dedicated to the rapid dissemination of research in the fields of oncology and pharmacology. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this journal has embraced the open access model, ensuring that critical cancer-related research is freely accessible to a global audience. With an impressive impact factor reflected by its Q2 ranking in both the Oncology and Pharmacology (medical) categories for 2023, as well as Scopus rankings placing it in the top 91st percentile in pharmacology and the 84th percentile in oncology, OncoTargets and Therapy stands out as a vital resource for researchers, clinicians, and students alike. The journal focuses on therapeutics, novel drug discoveries, and clinical trials, encouraging collaborative efforts to combat cancer effectively. By providing a platform for groundbreaking studies and comprehensive reviews, it plays a crucial role in advancing knowledge and practice in these critical areas of medical science.

Cancer Communications

Advancing the Frontiers of Cancer Research
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Blood Cancer Discovery

Catalyzing Change in Cancer Research Landscapes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

CLINICAL & EXPERIMENTAL METASTASIS

Illuminating Pathways in Cancer Progression
Publisher: SPRINGERISSN: 0262-0898Frequency: 6 issues/year

CLINICAL & EXPERIMENTAL METASTASIS is a highly regarded academic journal dedicated to the study of cancer metastasis, published by Springer. With an ISSN of 0262-0898 and an E-ISSN of 1573-7276, this journal serves as a pivotal resource for researchers and professionals dedicated to understanding the complexities of metastatic disease. Based in the Netherlands, it boasts an impressive impact factor, solidifying its position in two major quartiles: Q2 in Cancer Research and Q1 in both Medicine (Miscellaneous) and Oncology for 2023. The journal not only ranks among the top tier in Medicine Oncology—84th out of 404—but also excels in Biochemistry, Genetics and Molecular Biology in Cancer Research, ranking 75th out of 230. With coverage spanning from 1983 to 2024, CLINICAL & EXPERIMENTAL METASTASIS presents cutting-edge research, reviews, and clinical studies that drive the field forward. This journal is essential for anyone looking to deepen their understanding of cancer metastasis and its underlying mechanisms.

Cancer Research Communications

Innovating cancer treatment through shared insights.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

CANCER INVESTIGATION

Advancing cancer research, one investigation at a time.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Trends in Cancer

Uncovering Breakthroughs in Cancer Biology and Therapy
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

CANCER AND METASTASIS REVIEWS

Unraveling the Mysteries of Cancer Dynamics
Publisher: SPRINGERISSN: 0167-7659Frequency: 4 issues/year

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Cancer Reports

Fostering collaboration in the fight against cancer.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

BRITISH JOURNAL OF CANCER

Advancing Cancer Knowledge Through Rigorous Research.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.